Olga Almacellas-Rabaiget

Olga Almacellas-Rabaiget

Auto-generated profile, based on publicly available information

Olga Almacellas-Rabaiget

Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2018 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SGSilvia Garcia‐Monclús
Silvia Garcia‐Monclús
RLRoser López‐Alemany
Roser López‐Alemany
OAOlga Almacellas‐Rabaiget
Olga Almacellas‐Rabaiget
DHDavid Herrero‐Martín
David Herrero‐Martín
JHJuan Huertas‐Martinez
Juan Huertas‐Martinez
OTOscar M Tirado
Oscar M Tirado
Ewing sarcoma (ES) is the second most common bone malignancy affecting children and young adults with poor prognosis due to high metastasis incidence. Our group previously described that EphA2, a tyrosine kinase receptor, promotes angiogenesis in Ewing sarcoma (ES) cells via ligand‐dependent signaling. Now we wanted to explore EphA2 ligand‐independent activity, controlled upon phosphorylation at S897 (p‐EphA2S897), as it has been linked to metastasis in several malignancies. By reverse genetic engineering we explored the phenotypic changes after EphA2 removal or reintroduction. Gene expression microarray was used to identify key players in EphA2 signaling. Mice were employed to reproduce metastatic processes from orthotopically implanted engineered cells. We established a correlation between ES cells aggressiveness and p‐EphA2S897. Moreover, stable overexpression of EphA2 in low EphA2 expression ES cells enhanced proliferation and migration, but not a non‐phosphorylable mutant (S987A). Consistently, silencing of EphA2 reduced tumorigenicity, migration and invasion in vitro, and lung metastasis incidence in experimental and spontaneous metastasis assays in vivo. A gene expression microarray revealed the implication of EphA2 in cell signaling, cellular movement and survival. ADAM19 knockdown by siRNA technology strongly reproduced the negative effects on cell migration observed after EphA2 silencing. Altogether, our results suggest that p‐EphA2S897 correlates with aggressiveness in ES, so blocking its function may be a promising treatment.

28 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LLLaura Lagares-Tena
Laura Lagares-Tena
SGSilvia García-Monclús
Silvia García-Monclús
RARoser Lopez Alemany
Roser Lopez Alemany
OAOlga Almacellas-Rabaiget
Olga Almacellas-Rabaiget
JHJuan Huertas-Martínez
Juan Huertas-Martínez
OTOscar M Tirado
Oscar M Tirado
Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway

1 February 2017 in Cancer Letters
Verified
Journal Article
Closed access
JHJuan Huertas-Martínez
Juan Huertas-Martínez
FCFranck Court*
Franck Court*
SRSantiago Rello-Varona
Santiago Rello-Varona
DHDavid Herrero-Martín
David Herrero-Martín
OAOlga Almacellas-Rabaiget
Olga Almacellas-Rabaiget
OTOscar M Tirado
Oscar M Tirado

1 April 2020 in Cancer Letters
Verified
Journal Article
Closed access
OAOlga Almacellas-Rabaiget
Olga Almacellas-Rabaiget
PMPaola Monaco
Paola Monaco
JHJuan Huertas-Martinez
Juan Huertas-Martinez
SGSilvia García-Monclús
Silvia García-Monclús
MCMariona Chicon-Bosch
Mariona Chicon-Bosch
OTOscar M Tirado
Oscar M Tirado

12 February 2024 in SLAS Discovery
Verified
Journal Article
Open access
IFInés Fallon
Inés Fallon
HHHenar Hernando
Henar Hernando
OAOlga Almacellas-Rabaiget
Olga Almacellas-Rabaiget
BMBerta Marti-Fuster
Berta Marti-Fuster
CSCesare Spadoni
Cesare Spadoni
EMEva Méndez
Eva Méndez
Pediatric brain tumors (PBTs) represent about 25% of all pediatric cancers and are the most common solid tumors in children and adolescents. Medulloblastoma (MB) is the most frequently occurring malignant PBT, accounting for almost 10% of all pediatric cancer deaths. MB Group 3 (MB G3) accounts for 25-30% of all MB cases and has the worst outcome, particularly when associated with MYC amplification. However, no targeted treatments for this group have been developed so far. Here we describe a unique high throughput screening (HTS) platform specifically designed to identify new therapies for MB G3. The platform incorporates optimized and validated 2D and 3D efficacy and toxicity models, that account for tumor heterogenicity, limited efficacy and unacceptable toxicity from the very early stage of drug discovery. The platform has been validated by conducting a pilot HTS campaign with a 1280 lead-like compound library. Results showed 8 active compounds, targeting MB reported targets and several are currently approved or in clinical trials for pediatric patients with PBTs, including MB. Moreover, hits were combined to avoid tumor resistance, identifying 3 synergistic pairs, one of which is currently under clinical study for recurrent MB and other PBTs.